ClinicalTrials.gg
CompletedNCT04359914NCoVUpdated Jan 29, 2024

Neurocognitive Impairment in Patients With COVID-19

An observational study in Critical Illness, COVID-19 and Central Nervous System Injury, sponsored by University of Rostock. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-01-29.

Primary conditionCOVID-19Registry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name COVID-19.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Rostock · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
118
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 226 studies in COVID-19 with a site in Germany — 21 open to participants now, 27 under way, 7 of them phase 3. COVID-19 · Germany.

Enrollment
70th of 94
118 · median 410
Started
2020
with 108 others
Observational
94 of 226
11 open now
Registered
33rd of 226
by date

Among the 226 studies in COVID-19 with a site in Germany, this one is the 70th largest by enrollment of the 94 observational ones that give a count, is one of 109 that started in 2020, is one of 94 observational ones, and was the 33rd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

21 of the 226 studies in COVID-19 with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 226 studies in COVID-19 with a site in Germany, or all of them as a file.
02

Study summary

Delirium and acute neurocognitive impairment are increasingly observed in adult and pediatric patients with COVID-19. Prospective clinical studies combining clinical and laboratory examinations including specific biomarkers of neuroaxonal injury were not performed for COVID-19. The value of biomarkers of neuroaxonal injury was proven in preliminary studies. These biomarkers could thus contribute to the systematic detection of neurocognitive impairment in patients with COVID-19. Due to worldwide increasing numbers of hospitalized patients with COVID-19, biomarkers of neuroaxonal injury are highly valuable to detect and monitor cognitive impairment, especially with regard to limited resources available to perform time-consuming brain imaging.

Biomarkers of neuroaxonal injury are therefore not only of great interest to detect neurocognitive impairment but also to quantify the severity of brain injury in patients with COVID-19.

Read the detailed description

This is a multicenter observational study evaluating the incidence and severity of neurocognitive impairment in adult and pediatric patients with COVID-19. All study participants will be assessed by clinical and neurological examination as well as comprehensive laboratory tests using biomarkers of neuroaxonal injury at study day 1 (day of study inclusion), day 3, day 7 and day of hospital discharge. A panel of biomarkers (among others NSE, S100B and neurofilament proteins) will be measured. Clinical assessment will be performed using validated delirium tests (among others CAM-ICU, ICDSC) and scales to assess the neurocognitive performance of study participants before and three months after study inclusion (among others Short Blessed Test).

A group of patients with a comparable severity of disease but without the detection of SARS-Cov-2 will serve as control group and will undergo the same clinical and laboratory examinations.

We hypothesize, that:

  • patients with COVID-19 are more likely to develop delirium and neurocognitive impairment than patients without COVID-19
  • patients with a preexisting neurocognitive deficit are more vulnerable to neurocognitive impairment in the course of COVID-19 than patients without a preexisting neurocognitive deficit
  • Specific biomarkers of neuroaxonal injury correlate with the clinical severity of acute neurocognitive impairment and can predict the 3-month neurocognitive outcome of patients with COVID-19
03

Conditions studied

  • Critical Illness
  • COVID-19
  • Central Nervous System Injury
  • Delirium
  • Encephalopathy

Browse trials for

04

In context

COVID-19 Reclassified

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

This study's enrollment of 118 is below the median of 268 across 3,209 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

University of Rostock is the lead sponsor of 46 studies on the registry; 3 are open to participants now.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with suspected SARS-CoV-2 infection who are admitted to the study centers will be screened for study eligibility according to the inclusion and exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients of every age
  • admission to hospital with suspected COVID-19 disease
  • confirmed SARS-CoV-2 infection within 48 hours after admission

Exclusion criteria

Exclusion Criteria:

  • transferral from another hospital
  • other acute central nervous system diseases (e.g. meningoencephalitis, intracerebral ischemia or hemorrhage)
  • confirmed SARS-CoV-2 infection later than 48 hours after hospital admission
  • participation in another interventional study
  • no written from patient or legal representative
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
118 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • NCoV-A-COVID

    * adult patients of every age * admission to hospital with suspected COVID-19 disease * confirmed SARS-CoV-2 infection within 48 hours after admission

  • NCoV-A-CONTROL

    * adult patients of every age * admission to hospital with suspected COVID-19 disease * exclusion of SARS-CoV-2 infection within 48 hours after admission

  • NCoV-P-COVID

    * pediatric patients * admission to hospital with suspected COVID-19 disease * confirmed SARS-CoV-2 infection within 48 hours after admission

  • NCoV-P-CONTROL

    * pediatric patient * admission to hospital with suspected COVID-19 disease * exclusion of SARS-CoV-2 infection within 48 hours after admission

07

What researchers measure

Primary outcomes

  1. Incidence of delirium/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19

    Assessment of neurocognitive impairment using validated tools

    Time frame: Day 90

  2. Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19

    Measurement of biomarker levels (e.g. NSE, S100B, neurofilament proteins) derived from blood samples

    Time frame: Change from baseline biomarker levels at day 28

  3. Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19

    Assessment of the neurocognitive performance of patients using validated tests (e.g. Short Blessed Test)

    Time frame: Day 90

  4. Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19

    Assessment of the change in the neurocognitive performance of patients using validated tests (e.g. IQCODE)

    Time frame: Change from baseline IQCODE results at day 90

Secondary outcomes

  1. Quality of life in patients with COVID-19 compared to patients without COVID-19 after hospital discharge

    Assessment of the overall quality of life using validated tests \[e.g. Modified Rankin Scale with a range from 0 (no symptoms) to 6 (dead)\]

    Time frame: Day 90

  2. Length of hospital stay in patients with COVID-19 compared to patients without COVID-19

    Cumulative days in hospital

    Time frame: 1 year

  3. 90-day survival in patients with COVID-19 compared to patients without COVID-19

    Survival after 90 days

    Time frame: Day 90

08

Study locations

1 site
  • Department of Anesthesiology and Intensive Care Medicine, University Medical Center Rostock
    Rostock, Mecklenburg-Vorpommern D-18057, Germany
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Mar 2021, 11 months.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 11 months is below that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2020
First posted
Apr 24, 2020
StartActual
Apr 15, 2020
Primary completionActual
Mar 31, 2021
CompletionActual
Dec 31, 2023
Last update
Jan 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04359914
Lead sponsor
University of Rostock
Responsible party
Dr. Johannes Ehler, MD (PD Dr. med. Johannes Ehler, MD, University of Rostock) — Principal investigator
First posted
Apr 24, 2020
Start date
Apr 15, 2020
Primary completion
Mar 31, 2021
Completion
Dec 31, 2023
Last update
Jan 29, 2024

Study contacts

Johannes Ehler, MD
principal investigator · University of Rostock

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion